Montelukast

Routes
Oral (PO)
Half-Life (t½)
PO: 4h
Formula
C35H36ClNO3S
Molecular Weight
586.18 g/mol
PubChem CID
5281040
Aliases
Singulair

Pharmacological Mechanism

Leukotriene CysLT1 receptor antagonist — blocks LTD4 / LTE4 bronchoconstriction. Adjunctive asthma + allergic rhinitis. FDA black-box (2020) for neuropsychiatric adverse events including suicidality.

Half-Life & Elimination Curve (PO: 4h)

100%50%25%12.5%0%0h0×t½4h1×t½8h2×t½12h3×t½16h4×t½20h5×t½0×t½ (0h): 100% remaining (~0.171 mg/L)1×t½ (4h): 50% remaining (~85.5 µg/L)2×t½ (8h): 25% remaining (~42.8 µg/L)3×t½ (12h): 12.5% remaining (~21.4 µg/L)4×t½ (16h): 6.3% remaining (~10.7 µg/L)5×t½ (20h): 3.1% remaining (~5.35 µg/L)
Plasma (PO)t½ Decay (4h)Effect Site (ke0)
  • 0×t½0h100% (0.171 mg/L)
  • 1×t½4h50% (85.5 µg/L)
  • 2×t½8h25% (42.8 µg/L)
  • 3×t½12h12.5% (21.4 µg/L)
  • 4×t½16h6.3% (10.7 µg/L)
  • 5×t½20h3.1% (5.35 µg/L)
Elimination t½4h (PO)
Rate Constant (ke)0.173 h⁻¹
Time to Peak (Tmax)2.65h
Est. Peak (Cmax)0.171 mg/L
Clearance (CL)4.16 L/h
97% Washout (5×t½)20h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References